세니젠

188260KOSDAQ

50.3 / 100

Reference Date: 2026-09-08

Financial Score7.0 / 40

News Sentiment21.3 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Slightly up 2.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Senigen is a food safety specialist company established in 2005, leveraging advanced molecular diagnostic technologies like PCR and NGS to provide comprehensive food safety solutions. It has developed key products such as Genelix (high-sensitivity PCR) and GeNext (world's first NGS panel for foodborne pathogen detection), and is expanding into cosmetics and microbiome industries.

Number of Employees

72people

Average Salary

55.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

11.42Industry Average 1.200.0Point

9.5x industry avg (risky)

ROE

-108.63Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

153.31Industry Average 100.000.5Point

1.5x industry avg (risky)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.0% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -84.6% (declining, 2yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
박정웅 세니젠 대표 “진단 넘어 신약으로”…엔도라이신 승부수
세니젠의 박정웅 대표가 AI 기반 신약 개발로 엔도라이신 분야에서의 혁신적 성장을 강조하며 기업의 미래 전망을 밝게 했다.
Positive
세니젠, 차세대 항균제 개발 나선다…AI로 후보물질 설계
세니젠이 AI 기술을 활용해 엔돌라이신 기반의 혁신적인 항생제 개발에 착수함으로써 긍정적인 시장 반응을 기대할 수 있다.
Positive
“항생제 내성균 잡는다”…세니젠, 엔도라이신 신약 개발 본격화
세니젠의 엔도라이신 신약 개발이 AI 기술 도입으로 가속화되어 긍정적인 시장 반응을 기대할 수 있다.

Detailed Momentum

52-week position5.0Point

52w mid range (52%)

Current 2,035Won52-week high 2,53552-week low 1,484

1-month return4.0Point

1m +2.78% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral기업설명회(IR)개최2026-09-03
Neutral기업설명회(IR)개최2026-08-27
Neutral주식등의대량보유상황보고서(일반)2026-08-21
Neutral기타경영사항(자율공시) ([국책과제 선정]2026년 K-HERO 육성·지원사업(글로벌 선도를 위한 AI기반 항생제 내성균 타켓 엔도라이신 패혈증 치료제 개발))2026-08-20
Neutral반기보고서 (2026.06)2026-08-13